Erasca, Inc. (ERAS)
NASDAQ: ERAS · Real-Time Price · USD
16.80
+1.32 (8.53%)
At close: Nov 11, 2026, 4:00 PM EST
16.85
+0.05 (0.31%)
After-hours: Nov 11, 2026, 5:39 PM EST
Erasca Employees
Erasca had 103 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Erasca the 31,244th largest employer in the world and 3,993rd in the United States.
Employees
103
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,788,573
Market Cap
5.88B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 103 | 0 | - |
| Dec 31, 2024 | 103 | -23 | -18.25% |
| Dec 31, 2023 | 126 | -3 | -2.33% |
| Dec 31, 2022 | 129 | 6 | 4.88% |
| Dec 31, 2021 | 123 | 21 | 20.59% |
| Jun 30, 2021 | 102 | - | - |
| Mar 31, 2021 | 102 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ionis Pharmaceuticals | 1,480 |
| PTC Therapeutics | 991 |
| Travere Therapeutics | 497 |
| Mirum Pharmaceuticals | 470 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
| Edgewise Therapeutics | 133 |
| Definium Therapeutics | 106 |
ERAS News
- 9 hours ago - Erasca Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 1 day ago - Erasca Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 7 days ago - Tango Therapeutics, Erasca initiate vopimetostat with ERAS-0015 study - TheFly
- 7 days ago - Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 - GlobeNewsWire
- 8 days ago - Erasca to Present at Upcoming Conferences in November - GlobeNewsWire
- 19 days ago - ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law - Business Wire
- 5 weeks ago - Erasca participates in a conference call with JPMorgan - TheFly
- 7 weeks ago - Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims - GlobeNewsWire